{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:16:13Z","timestamp":1776071773203,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11060-026-05434-5","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:59:40Z","timestamp":1773248380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging systemic treatment strategies for vestibular schwannoma"],"prefix":"10.1007","volume":"177","author":[{"given":"Sai Chandan","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Karim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Feghali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"2","key":"5434_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11060-015-1827-9","volume":"124","author":"VR Kshettry","year":"2015","unstructured":"Kshettry VR, Hsieh JK, Ostrom QT, Kruchko C, Barnholtz-Sloan JS (2015) Incidence of vestibular schwannomas in the united States. J Neurooncol 124(2):223\u2013228. https:\/\/doi.org\/10.1007\/s11060-015-1827-9","journal-title":"J Neurooncol"},{"issue":"9","key":"5434_CR2","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","volume":"24","author":"SR Plotkin","year":"2022","unstructured":"Plotkin SR, Messiaen L, Legius E et al (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Sci 24(9):1967\u20131977. https:\/\/doi.org\/10.1016\/j.gim.2022.05.007","journal-title":"Genet Sci"},{"issue":"1","key":"5434_CR3","doi-asserted-by":"publisher","first-page":"vdae107","DOI":"10.1093\/noajnl\/vdae107","volume":"6","author":"S Guo","year":"2024","unstructured":"Guo S, Zheng X, Chen W et al (2024) From bench to bedside: advancing towards therapeutic treatment of vestibular schwannomas. Neuro-Oncol Adv 6(1):vdae107. https:\/\/doi.org\/10.1093\/noajnl\/vdae107","journal-title":"Neuro-Oncol Adv"},{"issue":"2","key":"5434_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/ijms22020690","volume":"22","author":"S Bachir","year":"2021","unstructured":"Bachir S, Shah S, Shapiro S et al (2021) Neurofibromatosis type 2 (NF2) and the implications for vestibular Schwannoma and meningioma pathogenesis. Int J Mol Sci 22(2):690. https:\/\/doi.org\/10.3390\/ijms22020690","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5434_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1055\/s-0035-1564591","volume":"77","author":"AN Anaizi","year":"2016","unstructured":"Anaizi AN, DiNapoli VV, Pensak M, Theodosopoulos PV (2016) Small vestibular schwannomas: does surgery remain a viable treatment option? J Neurol Surg Part B Skull Base 77(3):212\u2013218. https:\/\/doi.org\/10.1055\/s-0035-1564591","journal-title":"J Neurol Surg Part B Skull Base"},{"key":"5434_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/DDDT.S280069","volume":"15","author":"J Long","year":"2021","unstructured":"Long J, Zhang Y, Huang X, Ren J, Zhong P, Wang B (2021) A review of drug therapy in vestibular Schwannoma. Drug Des Devel Ther 15:75\u201385. https:\/\/doi.org\/10.2147\/DDDT.S280069","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"5434_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11912-023-01388-3","volume":"25","author":"EC Cumpston","year":"2023","unstructured":"Cumpston EC, Rhodes SD, Yates CW (2023) Advances in targeted therapy for neurofibromatosis type 2 (NF2)-Associated vestibular schwannomas. Curr Oncol Rep 25(5):531\u2013537. https:\/\/doi.org\/10.1007\/s11912-023-01388-3","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"5434_CR8","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.3390\/ijms23105462","volume":"23","author":"R Tamura","year":"2022","unstructured":"Tamura R, Toda M (2022) A critical overview of targeted therapies for vestibular Schwannoma. Int J Mol Sci 23(10):5462. https:\/\/doi.org\/10.3390\/ijms23105462","journal-title":"Int J Mol Sci"},{"key":"5434_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.wneu.2016.10.060","volume":"98","author":"AC Lawson McLean","year":"2017","unstructured":"Lawson McLean AC, Rosahl SK (2017) Growth dynamics of intracranial tumors in patients with neurofibromatosis type 2. World Neurosurg 98:152\u2013161. https:\/\/doi.org\/10.1016\/j.wneu.2016.10.060","journal-title":"World Neurosurg"},{"issue":"1","key":"5434_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-4-16","volume":"4","author":"Evans DgR","year":"2009","unstructured":"Evans DgR (2009) Neurofibromatosis type 2 (NF2): A clinical and molecular review. Orphanet J Rare Dis 4(1):16. https:\/\/doi.org\/10.1186\/1750-1172-4-16","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"5434_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3171\/jns.2002.96.2.0223","volume":"96","author":"VF Mautner","year":"2002","unstructured":"Mautner VF, Baser ME, Thakkar SD, Feigen UM, Friedman JM, Kluwe L (2002) Vestibular Schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study. J Neurosurg 96(2):223\u2013228. https:\/\/doi.org\/10.3171\/jns.2002.96.2.0223","journal-title":"J Neurosurg"},{"issue":"9","key":"5434_CR12","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/cancers11091376","volume":"11","author":"I Gugel","year":"2019","unstructured":"Gugel I, Grimm F, Liebsch M et al (2019) Impact of surgery on Long-Term results of hearing in neurofibromatosis Type-2 associated vestibular schwannomas. Cancers 11(9):1376. https:\/\/doi.org\/10.3390\/cancers11091376","journal-title":"Cancers"},{"key":"5434_CR13","doi-asserted-by":"publisher","first-page":"e820","DOI":"10.1016\/j.wneu.2022.12.118","volume":"171","author":"GS Sri Krishna","year":"2023","unstructured":"Sri Krishna GS, Pahwa B, Jagdevan A, Singh M, Kale S, Agrawal D (2023) Tumor control and hearing preservation after gamma knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2-A retrospective analysis of 133 tumors. World Neurosurg 171:e820\u2013e827. https:\/\/doi.org\/10.1016\/j.wneu.2022.12.118","journal-title":"World Neurosurg"},{"issue":"2","key":"5434_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/01.mao.0000180484.24242.54","volume":"27","author":"BA Neff","year":"2006","unstructured":"Neff BA, Welling DB, Akhmametyeva E, Chang LS (2006) The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 27(2):197\u2013208. https:\/\/doi.org\/10.1097\/01.mao.0000180484.24242.54","journal-title":"Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol"},{"issue":"3","key":"5434_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/bpa.12125","volume":"24","author":"DA Hilton","year":"2014","unstructured":"Hilton DA, Hanemann CO (2014) Schwannomas and their pathogenesis. Brain Pathol Zurich Switz 24(3):205\u2013220. https:\/\/doi.org\/10.1111\/bpa.12125","journal-title":"Brain Pathol Zurich Switz"},{"issue":"5","key":"5434_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2015.125","volume":"35","author":"AM Petrilli","year":"2015","unstructured":"Petrilli AM, Fern\u00e1ndez-Valle C (2015) Role of Merlin\/NF2 inactivation in tumor biology. Oncogene 35(5):537\u2013548. https:\/\/doi.org\/10.1038\/onc.2015.125","journal-title":"Oncogene"},{"key":"5434_CR17","doi-asserted-by":"publisher","unstructured":"Colciago A, Melfi S, Giannotti G et al (2015) Tumor suppressor Nf2\/merlin drives Schwann cell changes following electromagnetic field exposure through Hippo-dependent mechanisms. Cell Death Discovery 1(1). https:\/\/doi.org\/10.1038\/cddiscovery.2015.21","DOI":"10.1038\/cddiscovery.2015.21"},{"issue":"3","key":"5434_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/mao.0b013e3181d2777f","volume":"31","author":"Z Ahmad","year":"2010","unstructured":"Ahmad Z, Brown CM, Patel AK, Ryan AF, Ongkeko R, Doherty JK (2010) Merlin knockdown in human Schwann cells. Otology Neurotology 31(3):460\u2013466. https:\/\/doi.org\/10.1097\/mao.0b013e3181d2777f","journal-title":"Otology Neurotology"},{"issue":"4","key":"5434_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/ng930","volume":"31","author":"C Fernandez-Valle","year":"2002","unstructured":"Fernandez-Valle C, Tang Y, Ricard J et al (2002) Paxillin binds Schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet 31(4):354\u2013362. https:\/\/doi.org\/10.1038\/ng930","journal-title":"Nat Genet"},{"issue":"9","key":"5434_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1101\/gad.1054603","volume":"17","author":"D Lallemand","year":"2003","unstructured":"Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI (2003) NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 17(9):1090\u20131100. https:\/\/doi.org\/10.1101\/gad.1054603","journal-title":"Genes Dev"},{"issue":"5","key":"5434_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.devcel.2010.10.008","volume":"19","author":"AB Gladden","year":"2010","unstructured":"Gladden AB, Hebert AM, Schneeberger EE, McClatchey AI (2010) The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional Polarity complex. Dev Cell 19(5):727\u2013739. https:\/\/doi.org\/10.1016\/j.devcel.2010.10.008","journal-title":"Dev Cell"},{"issue":"5","key":"5434_CR22","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1083\/jcb.200703010","volume":"177","author":"M Curto","year":"2007","unstructured":"Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI (2007) Contact-dependent Inhibition of EGFR signaling by Nf2\/Merlin. J Cell Biol 177(5):893\u2013903. https:\/\/doi.org\/10.1083\/jcb.200703010","journal-title":"J Cell Biol"},{"issue":"4","key":"5434_CR23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.bbrc.2005.12.122","volume":"340","author":"JY Lim","year":"2006","unstructured":"Lim JY, Kim H, Jeun SS, Kang SG, Lee KJ (2006) Merlin inhibits growth hormone-regulated Raf-ERKs pathways by binding to Grb2 protein. Biochem Biophys Res Commun 340(4):1151\u20131157. https:\/\/doi.org\/10.1016\/j.bbrc.2005.12.122","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"5434_CR24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/nen.0b013e318093e555","volume":"66","author":"C Flaiz","year":"2007","unstructured":"Flaiz C, Kaempchen K, Matthies C, Hanemann CO (2007) Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannomas. J Neuropathol Exp Neurol 66(7):608\u2013616. https:\/\/doi.org\/10.1097\/nen.0b013e318093e555","journal-title":"J Neuropathol Exp Neurol"},{"issue":"13","key":"5434_CR25","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1523\/JNEUROSCI.4865-05.2006","volume":"26","author":"Y Nakai","year":"2006","unstructured":"Nakai Y, Zheng Y, MacCollin M, Ratner N (2006) Temporal control of Rac in Schwann cell-axon interaction is disrupted in NF2-mutant Schwannoma cells. J Neurosci Off J Soc Neurosci 26(13):3390\u20133395. https:\/\/doi.org\/10.1523\/JNEUROSCI.4865-05.2006","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"1","key":"5434_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/s1534-5807(01)00009-0","volume":"1","author":"RJ Shaw","year":"2001","unstructured":"Shaw RJ, Paez JG, Curto M et al (2001) The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 1(1):63\u201372. https:\/\/doi.org\/10.1016\/s1534-5807(01)00009-0","journal-title":"Dev Cell"},{"issue":"5","key":"5434_CR27","first-page":"471","volume":"6","author":"AM Petrilli","year":"2014","unstructured":"Petrilli AM, Fuse MA, Donnan MS et al (2014) A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2. Am J Transl Res 6(5):471\u2013493","journal-title":"Am J Transl Res"},{"issue":"52","key":"5434_CR28","doi-asserted-by":"publisher","first-page":"18200","DOI":"10.1073\/pnas.0405971102","volume":"101","author":"R Rong","year":"2004","unstructured":"Rong R, Tang X, Gutmann DH, Ye K (2004) Neurofibromatosis 2 (NF2) tumor suppressor Merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A 101(52):18200\u201318205. https:\/\/doi.org\/10.1073\/pnas.0405971102","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5434_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2014.05.001","volume":"26","author":"W Li","year":"2014","unstructured":"Li W, Cooper J, Zhou L et al (2014) Merlin\/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated Inhibition of the Hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell 26(1):48\u201360. https:\/\/doi.org\/10.1016\/j.ccr.2014.05.001","journal-title":"Cancer Cell"},{"issue":"4","key":"5434_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","volume":"140","author":"W Li","year":"2010","unstructured":"Li W, You L, Cooper J et al (2010) Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4DCAF1 in the nucleus. Cell 140(4):477\u2013490. https:\/\/doi.org\/10.1016\/j.cell.2010.01.029","journal-title":"Cell"},{"issue":"2","key":"5434_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.5152\/iao.2018.4929","volume":"14","author":"H Sass","year":"2018","unstructured":"Sass H, Cay\u00e9-Thomasen P (2018) Contemporary molecular biology of sporadic vestibular schwannomas: A systematic review and clinical implications. J Int Adv Otol 14(2):322\u2013329. https:\/\/doi.org\/10.5152\/iao.2018.4929","journal-title":"J Int Adv Otol"},{"issue":"3","key":"5434_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3171\/2016.10.JNS161384","volume":"128","author":"AL H\u00e5vik","year":"2018","unstructured":"H\u00e5vik AL, Bruland O, Myrseth E et al (2018) Genetic landscape of sporadic vestibular Schwannoma. J Neurosurg 128(3):911\u2013922. https:\/\/doi.org\/10.3171\/2016.10.JNS161384","journal-title":"J Neurosurg"},{"issue":"1","key":"5434_CR33","doi-asserted-by":"publisher","first-page":"5470","DOI":"10.1038\/s41598-017-05769-0","volume":"7","author":"H Chen","year":"2017","unstructured":"Chen H, Xue L, Wang H, Wang Z, Wu H (2017) Differential NF2 gene status in sporadic vestibular schwannomas and its prognostic impact on tumour growth patterns. Sci Rep 7(1):5470. https:\/\/doi.org\/10.1038\/s41598-017-05769-0","journal-title":"Sci Rep"},{"issue":"1","key":"5434_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2377-11-9","volume":"11","author":"G Rousseau","year":"2011","unstructured":"Rousseau G, Noguchi T, Bourdon V, Sobol H, Olschwang S (2011) SMARCB1\/INI1 germline mutations contribute to 10% of sporadic schwannomatosis. BMC Neurol 11(1):9. https:\/\/doi.org\/10.1186\/1471-2377-11-9","journal-title":"BMC Neurol"},{"issue":"6","key":"5434_CR35","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00381-017-3340-2","volume":"33","author":"R Caltabiano","year":"2017","unstructured":"Caltabiano R, Magro G, Polizzi A et al (2017) A mosaic pattern of INI1\/SMARCB1 protein expression distinguishes schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas. Childs Nerv Syst 33(6):933\u2013940. https:\/\/doi.org\/10.1007\/s00381-017-3340-2","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"5434_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11060-017-2711-6","volume":"137","author":"I Paganini","year":"2018","unstructured":"Paganini I, Capone GL, Vitte J et al (2018) Double somatic SMARCB1 and NF2 mutations in sporadic spinal Schwannoma. J Neurooncol 137(1):33\u201338. https:\/\/doi.org\/10.1007\/s11060-017-2711-6","journal-title":"J Neurooncol"},{"issue":"9","key":"5434_CR37","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/jamaneurol.2017.1406","volume":"74","author":"ON Pathmanaban","year":"2017","unstructured":"Pathmanaban ON, Sadler KV, Kamaly-Asl ID et al (2017) Association of genetic predisposition with solitary Schwannoma or meningioma in children and young adults. JAMA Neurol 74(9):1123\u20131129. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1406","journal-title":"JAMA Neurol"},{"issue":"3","key":"5434_CR38","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.21873\/invivo.13929","volume":"39","author":"M Breun","year":"2025","unstructured":"Breun M, Schulz T, Monoranu CM et al (2025) Pathogenic variants and allele loss of the NF2 and LZTR1 gene in sporadic vestibular Schwannoma. Vivo Athens Greece 39(3):1251\u20131261. https:\/\/doi.org\/10.21873\/invivo.13929","journal-title":"Vivo Athens Greece"},{"issue":"2","key":"5434_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/MAO.0b013e31823e287f","volume":"33","author":"ML Bush","year":"2012","unstructured":"Bush ML, Burns SS, Oblinger J et al (2012) Treatment of vestibular Schwannoma cells with erbb inhibitors. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 33(2):244\u2013257. https:\/\/doi.org\/10.1097\/MAO.0b013e31823e287f","journal-title":"Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol"},{"issue":"5","key":"5434_CR40","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/MAO.0b013e31821f7d88","volume":"32","author":"ZK Ahmad","year":"2011","unstructured":"Ahmad ZK, Brown CM, Cueva RA, Ryan AF, Doherty JK (2011) ErbB expression, activation, and Inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 32(5):841\u2013847. https:\/\/doi.org\/10.1097\/MAO.0b013e31821f7d88","journal-title":"Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol"},{"issue":"9","key":"5434_CR41","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","volume":"14","author":"MA Karajannis","year":"2012","unstructured":"Karajannis MA, Legault G, Hagiwara M et al (2012) Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncol 14(9):1163\u20131170. https:\/\/doi.org\/10.1093\/neuonc\/nos146","journal-title":"Neuro-Oncol"},{"issue":"7","key":"5434_CR42","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","volume":"31","author":"SR Plotkin","year":"2010","unstructured":"Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG (2010) Erlotinib for progressive vestibular Schwannoma in neurofibromatosis 2 patients. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 31(7):1135\u20131143. https:\/\/doi.org\/10.1097\/MAO.0b013e3181eb328a","journal-title":"Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol"},{"issue":"24","key":"5434_CR43","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/nejmoa2400985","volume":"390","author":"SR Plotkin","year":"2024","unstructured":"Plotkin SR, Yohay KH, Nghiemphu PL et al (2024) Brigatinib in NF2 -Related schwannomatosis with progressive tumors. N Engl J Med 390(24):2284\u20132294. https:\/\/doi.org\/10.1056\/nejmoa2400985","journal-title":"N Engl J Med"},{"issue":"2","key":"5434_CR44","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/neuonc\/not150","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis MA, Legault G, Hagiwara M et al (2014) Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncol 16(2):292\u2013297. https:\/\/doi.org\/10.1093\/neuonc\/not150","journal-title":"Neuro-Oncol"},{"issue":"2","key":"5434_CR45","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11060-017-2447-3","volume":"133","author":"S Goutagny","year":"2017","unstructured":"Goutagny S, Giovannini M, Kalamarides M (2017) A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas. J Neurooncol 133(2):443\u2013445. https:\/\/doi.org\/10.1007\/s11060-017-2447-3","journal-title":"J Neurooncol"},{"issue":"2","key":"5434_CR46","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny S, Raymond E, Esposito-Farese M et al (2015) Phase II study of mTORC1 Inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol 122(2):313\u2013320. https:\/\/doi.org\/10.1007\/s11060-014-1710-0","journal-title":"J Neurooncol"},{"issue":"1","key":"5434_CR47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00129492-200501000-00017","volume":"26","author":"P Cay\u00e9-Thomasen","year":"2005","unstructured":"Cay\u00e9-Thomasen P, Werther K, Nalla A et al (2005) VEGF and VEGF receptor-1 concentration in vestibular Schwannoma homogenates correlates to tumor growth rate. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 26(1):98\u2013101. https:\/\/doi.org\/10.1097\/00129492-200501000-00017","journal-title":"Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol"},{"issue":"47","key":"5434_CR48","doi-asserted-by":"publisher","first-page":"14676","DOI":"10.1073\/pnas.1512570112","volume":"112","author":"X Gao","year":"2015","unstructured":"Gao X, Zhao Y, Stemmer-Rachamimov AO et al (2015) Anti-VEGF treatment improves neurological function and augments radiation response in NF2 Schwannoma model. Proc Natl Acad Sci U S A 112(47):14676\u201314681. https:\/\/doi.org\/10.1073\/pnas.1512570112","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"5434_CR49","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1055\/s-0038-1676628","volume":"80","author":"DE Killeen","year":"2019","unstructured":"Killeen DE, Klesse L, Tolisano AM, Hunter JB, Kutz JW (2019) Long-Term effects of bevacizumab on vestibular Schwannoma volume in neurofibromatosis type 2 patients. J Neurol Surg Part B Skull Base 80(5):540\u2013546. https:\/\/doi.org\/10.1055\/s-0038-1676628","journal-title":"J Neurol Surg Part B Skull Base"},{"key":"5434_CR50","doi-asserted-by":"publisher","unstructured":"Alanin MC, Klausen C, Caye-Thomasen P et al (2015) The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol -. Head Neck Surg 272(12):3627\u20133633. https:\/\/doi.org\/10.1007\/s00405-014-3398-3","DOI":"10.1007\/s00405-014-3398-3"},{"issue":"2","key":"5434_CR51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2176\/nmc.oa.2019-0194","volume":"60","author":"M Fujii","year":"2020","unstructured":"Fujii M, Ichikawa M, Iwatate K et al (2020) Bevacizumab therapy of neurofibromatosis type 2 associated vestibular Schwannoma in Japanese patients. Neurol Med Chir (Tokyo) 60(2):75\u201382. https:\/\/doi.org\/10.2176\/nmc.oa.2019-0194","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"14","key":"5434_CR52","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Ye X, Duda DG et al (2016) Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-Associated vestibular schwannomas. J Clin Oncol Off J Am Soc Clin Oncol 34(14):1669\u20131675. https:\/\/doi.org\/10.1200\/JCO.2015.64.3817","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"5434_CR53","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/0194599818809085","volume":"160","author":"P Sverak","year":"2019","unstructured":"Sverak P, Adams ME, Haines SJ et al (2019) Bevacizumab for hearing preservation in neurofibromatosis type 2: emphasis on Patient-Reported outcomes and toxicities. Otolaryngol\u2013Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg 160(3):526\u2013532. https:\/\/doi.org\/10.1177\/0194599818809085","journal-title":"Otolaryngol\u2013Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg"},{"issue":"6","key":"5434_CR54","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Merker VL, Halpin C et al (2012) Bevacizumab for progressive vestibular Schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 33(6):1046\u20131052. https:\/\/doi.org\/10.1097\/MAO.0b013e31825e73f5","journal-title":"Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol"},{"issue":"4","key":"5434_CR55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/nop\/npv065","volume":"3","author":"KA Morris","year":"2016","unstructured":"Morris KA, Golding JF, Axon PR et al (2016) Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncol Pract 3(4):281\u2013289. https:\/\/doi.org\/10.1093\/nop\/npv065","journal-title":"Neuro-Oncol Pract"},{"issue":"35","key":"5434_CR56","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","volume":"37","author":"SR Plotkin","year":"2019","unstructured":"Plotkin SR, Duda DG, Muzikansky A et al (2019) Multicenter, Prospective, phase II and biomarker study of High-Dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular Schwannoma. J Clin Oncol Off J Am Soc Clin Oncol 37(35):3446\u20133454. https:\/\/doi.org\/10.1200\/JCO.19.01367","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"5434_CR57","doi-asserted-by":"publisher","first-page":"e28228","DOI":"10.1002\/pbc.28228","volume":"67","author":"S Renzi","year":"2020","unstructured":"Renzi S, Michaeli O, Salvador H et al (2020) Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence. Pediatr Blood Cancer 67(5):e28228. https:\/\/doi.org\/10.1002\/pbc.28228","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"5434_CR58","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","volume":"124","author":"A Hochart","year":"2015","unstructured":"Hochart A, Gaillard V, Baroncini M et al (2015) Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neurooncol 124(2):229\u2013236. https:\/\/doi.org\/10.1007\/s11060-015-1828-8","journal-title":"J Neurooncol"},{"issue":"6","key":"5434_CR59","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/neuonc\/noz051","volume":"21","author":"MA Karajannis","year":"2019","unstructured":"Karajannis MA, Hagiwara M, Schreyer M, Haque S (2019) Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular Schwannoma. Neuro-Oncol 21(6):822\u2013824. https:\/\/doi.org\/10.1093\/neuonc\/noz051","journal-title":"Neuro-Oncol"},{"issue":"1","key":"5434_CR60","doi-asserted-by":"publisher","first-page":"vdaa023","DOI":"10.1093\/noajnl\/vdaa023","volume":"2","author":"CJ Hannan","year":"2020","unstructured":"Hannan CJ, Lewis D, O\u2019Leary C et al (2020) The inflammatory microenvironment in vestibular Schwannoma. Neuro-Oncol Adv 2(1):vdaa023. https:\/\/doi.org\/10.1093\/noajnl\/vdaa023","journal-title":"Neuro-Oncol Adv"},{"issue":"12","key":"5434_CR61","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/biology9120434","volume":"9","author":"F Finetti","year":"2020","unstructured":"Finetti F, Travelli C, Ercoli J, Colombo G, Buoso E, Trabalzini L (2020) Prostaglandin E2 and cancer: insight into tumor progression and immunity. Biology 9(12):434. https:\/\/doi.org\/10.3390\/biology9120434","journal-title":"Biology"},{"issue":"4","key":"5434_CR62","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1227\/NEU.0b013e318208f5c7","volume":"68","author":"B Hong","year":"2011","unstructured":"Hong B, Krusche CA, Schwabe K et al (2011) Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas. Neurosurgery 68(4):1112\u20131117. https:\/\/doi.org\/10.1227\/NEU.0b013e318208f5c7","journal-title":"Neurosurgery"},{"issue":"1","key":"5434_CR63","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40478-019-0760-0","volume":"7","author":"F Behling","year":"2019","unstructured":"Behling F, Ries V, Skardelly M et al (2019) COX2 expression is associated with proliferation and tumor extension in vestibular Schwannoma but is not influenced by acetylsalicylic acid intake. Acta Neuropathol Commun 7(1):105. https:\/\/doi.org\/10.1186\/s40478-019-0760-0","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"5434_CR64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/MAO.0000000000000189","volume":"35","author":"CK Kandathil","year":"2014","unstructured":"Kandathil CK, Dilwali S, Wu CC et al (2014) Aspirin intake correlates with halted growth of sporadic vestibular Schwannoma in vivo. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 35(2):353\u2013357. https:\/\/doi.org\/10.1097\/MAO.0000000000000189","journal-title":"Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol"},{"issue":"6","key":"5434_CR65","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1177\/0194599819827812","volume":"160","author":"JP Marinelli","year":"2019","unstructured":"Marinelli JP, Lees KA, Tombers NM, Lohse CM, Carlson ML (2019) Impact of aspirin and other NSAID use on volumetric and linear growth in vestibular Schwannoma. Otolaryngol\u2013Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg 160(6):1081\u20131086. https:\/\/doi.org\/10.1177\/0194599819827812","journal-title":"Otolaryngol\u2013Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05434-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:37:54Z","timestamp":1776069474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05434-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["5434"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05434-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a topical review on systemic therapies in vestibular schwannoma and consequently, no institutional review board approval was needed to conduct the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}